EUCTR2017-000133-31-BE进行中（未招募）1 期
Combined hypofractionated stereotactic body radiotherapy with immunomodulating systemic therapy for inoperable recurrent head and neck cancer: detection of the maximum tolerated dose.
Z Gent0 个研究点目标入组 30 人开始时间: 2017年5月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?Histologically confirmed local, regional or combined locoregional recurrence of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx or cancer of unknown primary (CUP) in the neck in previously irradiated tissue, with former irradiation with curative intent.
- •?Patients with non-symptomatic distant metastases and local, regional or combined locoregional recurrence can be included.
- •?In case of non-metastatic disease, the recurrence must be primarily unresectable recurrence and/or patients refused surgery.
- •?Time interval 6-24 months after the end of the initial radio(chemo)therapy for primary head and neck cancer.
- •?Decision of the Head and Neck Tumor Boards at the recruiting centre to offer salvage radio(chemo)therapy, palliative chemotherapy or anti-PD-1 antibody treatment with nivolumab for cisplatin-refractory locoregional recurrent head and neck squamous cell carcinoma.
- •?Karnofsky performance status = 70.
- •?Age = 18 years old.
- •?Informed consent obtained, signed and dated before specific protocol procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 14
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •?Previous radiotherapy was for cT1-2 cN0 M0 glottic cancer.
- •Grade = 4 late toxicity after the initial radio(chemo)therapy.
- •?Brachytherapy as treatment for second primary / recurrence.
- •?Previous (combination with) immunotherapy for the primary or the recurrent squamous cell carcinoma.
- •?Impossibility of oral intake of cylophosphamide.
- •?For patients receiving cyclophosphamide: Necessary intake during therapy of allopurinol, amiodarone, digoxin, hydrochlorothiazide, indomethacin, phenobarbital, phenytoin, warfarin. clopidogrel, ticlopidine, carbamazepine, efavirenz, rifampicine, ritonavir
- •?High risk for arterial blow-out: 1 of following criteria is sufficient to exclude patients:
- •o(1) soft tissue necrosis
- •o(2) skin invasion of the recurrent cancer
- •o(3) circumferential involvement of > 180° of a carotid artery)
- •?Symptomatic distant metastases.
- •?Other uncontrolled second primary tumors.
- •?Pregnant or lactating women.
- •?Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
- •?Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study.
研究者
相似试验
尚未招募
2 期
Single fraction of proton stereotactic body radiotherapy (SBRT) versus multiple fraction of photon SBRT for bone metastatic patientsbone metastatic patientsbone metastasesbone metastatic paincancer patientsTCTR20220615009Radiation oncology division, Radiology Department, KCMH136
进行中（未招募）
1 期
Addition of stereotactic body radiotherapy (SBRT) to chemotherapy in locally advanced biliary tract cancersocally advanced biliary tract cancerMedDRA version: 21.0Level: LLTClassification code 10004586Term: Bile duct adenocarcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864EUCTR2014-003656-31-GBniversity College London81
进行中（未招募）
不适用
A trial looking at whether stereotactic radiotherapy together with chemotherapy is a useful treatment for people with locally advanced bile duct cancer (ABC-07)Biliary tract cancerMalignant neoplasm of other and unspecified parts of biliary tractCancerISRCTN10639376niversity College London83
已完成
不适用
Phase I Hybrid study: combined stereotactic radiotherapy and conventional fractionation in stage II and III non small cell lung cancer with peripheral tumors smaller than 5 cmNon small cell lung cancer10038666Lung cancerNL-OMON39053ederlands Kanker Instituut15
进行中（未招募）
不适用
Combined stereotactic radiotherapy and conventional fractionation in stage II and II lungcancer.SCLC stage III or inoperable stage IIMedDRA version: 14.1Level: PTClassification code 10062041Term: Lung infiltration malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10023779Term: Large cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10025036Term: Lung adenocarcinoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10062042Term: Lung neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029520Term: Non-small cell lung cancer stage IIIASystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10025082Term: Lung disorderSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 14.1Level: PTClassification code 10025031Term: Lung adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10025069Term: Lung carcinoma cell type unspecified stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10001250Term: Adenosquamous cell lung cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (inclEUCTR2012-002392-33-NLKI-AV